The Future of Health Economics offers a window into some of the most influential emerging issues in pharmacoeconomics; issues such as risk-sharing and alternative pricing models or the potential impact of radical new approaches such as personalized medicine; as well as exploring the changing role of government and regulators.
The pharmaceutical industry faces a well-documented perfect storm: on the one hand, the patent cliff; the lack of new blockbusters and, on the other, economic pressure on pricing from markets with growing expectations and shrinking budgets. In the face of such pressure, traditional health economics models no longer seem appropriate and yet what do we have to replace them? The growing focus on 'value' and 'cost effectiveness' are evidence of new emerging thinking although, even here, with the shift from medicine as cure to medicine as palliative, as a treatment for chronic illness and with the growing emphasis on preventative approaches, the landscape is complex and challenging.
The Future of Health Economics offers a window into some of the most influential emerging issues in pharmacoeconomics; issues such as risk-sharing and alternative pricing models or the potential impact of radical new approaches such as personalized medicine; as well as exploring the changing role of government and regulators.
Ulf Staginnus and Olivier Ethgen, themselves two of the most well-regarded practitioners in this field, have brought together some leading-edge thinkers from industry and academia around the world to provide the industry, policy-makers, regulators, health practitioners and academics with the raw material for their future scenarios.
The Future of Health Economics offers a window into some of the most influential emerging issues in pharmacoeconomics; issues such as risk-sharing and alternative pricing models or the potential impact of radical new approaches such as personalized medicine; as well as exploring the changing role of government and regulators.
Contents
Part I Innovation and Market Access: The role of value in market access and
pricing negotiations, Ed Schoonveld; Productivity, innovation and value-based
pricing, Larry Gorkin and Eugenia Gruzglin; Early optimisation of draft
evidence plans for market access, Michael Wonder and Edward Hornby; An
overview of market access agreements, Mondher Toumi, Julie Zard, Imene Ben
Abdallah, Claudio Jommi and Joshua Cohen; Coverage of orphan drugs, Thomas
Morel and Steven Simoens; Innovating in the changing market access
environment, Ulf Staginnus.
Part II Technological Changes and Demographics: The increasing economic
expectations of stratified and personalised medicine, Antonio Ramirez de
Arellano Serna; Electronic Health Economics (eHE), Olivier Ethgen, Justine
Slomian and Mel Walker; Population needs, opportunity costs and economic
methods for financial sustainability in health care systems, Stephen Birch
and Amiram Gafni; The fiscal impact of investments in healthcare, Mark
Connolly; Does health economics have a future in Asia?, Ning Lu and Eun Young
Bae.
Part III Decision-Making and Assessment: Patient preferences in health
technology assessment, Janine van Til and John Bridges; Multi-criteria
decision analysis, Olivier Ethgen and Kevin Marsh; Comparative effectiveness
from real-world evidence, Billy Amzal, Roman Casciano, Lamiae
Grimaldi-Bensouda and Lucien Abenhaim; Mathematical programming modeling to
optimise allocation of healthcare interventions, Nadia Demarteau, Baudouin
Standaert and Stephanie Earnshaw; Bridging health economics and capital
investment modeling methods to improve portfolio management, Essč Ifčbi Hervé
Akpo, Cédric Popa, Dogan Fidan and Omer Saka. Index.
Olivier Ethgen is an Associate Professor of Health Economics at the Department of Public Health Sciences, School of Medicine, University of Ličge, Belgium. He lectures in health economics (theory and applied modeling), decision sciences and pharmacoepidemiology.
Ulf Staginnus is a health economist and pharmaceutical executive with 20 years of international experience in the field of market access, pharmacoeconomics, pricing and reimbursement as well as health technology valuations within the biotechnology and pharmaceutical industry. Ulf is currently Vice President Value & Access, Region Europe with Shire in Zug, Switzerland.
